0001437749-26-017064
SEC filingEton Pharmaceuticals delivered a strong Q1 FY2026, achieving $24.3M in revenue and swinging to $2.4M in operating income and $1.6M in net income — driven by broad-based commercial execution across its rare disease portfolio and efficient working capital management.
Revenue increased 40.4% year-over-year to $24.3M, driven by higher sales across multiple products in Eton’s rare disease portfolio — specifically INCRELEX®, GALZIN®, ALKINDI SPRINKLE®, and Carglumic Acid — as well as the contribution from KHINDIVI™, which launched during the quarter. This growth reflects organic demand realization rather than acquisition-driven or one-time events. The Company’s inventory model — storing products at pharmacy distributor customer locations and recognizing revenue only when stock is pulled and shipped to fulfill specific patient orders — supports reliable, demand-triggered revenue recognition and reduces channel distortion.
Gross profit grew 49.4% to $14.7M, and gross margin remained stable at 60.7%. This consistency underscores disciplined pricing and predictable cost structure, even with the addition of KHINDIVI™ — a newly commercialized therapy that could have introduced margin volatility. Operating income improved dramatically to $2.4M from a $470K loss, representing a fundamental inflection in operational leverage. While R&D expenses increased due to KHINDIVI™ label expansion and ET-700 development, and G&A rose due to higher FDA fees and expanded headcount, these increases were more than offset by top-line growth and reduced cash outlay for inventory purchases.
Net cash provided by operating activities rose to $7.4M from $2.1M, primarily attributable to higher cash collections from product sales and lower cash outlay for inventory purchases — a direct outcome of the Company’s pull-through revenue model and improved working capital discipline. Capital expenditures totaled just $75K, reinforcing the asset-light nature of the business: no significant manufacturing or distribution infrastructure investment was required. Free cash flow totaled $7.3M, demonstrating strong conversion of earnings into liquid resources without reliance on external financing or non-recurring items. This efficiency supports continued investment in clinical development while maintaining financial flexibility.